SC 13G 1 c53454_sc13g.htm c53454_sc13g.htm
  UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Schedule 13G

Under the Securities Exchange Act of 1934

(Amendment No.      )* 		     
       
   


OMB APPROVAL

  OMB Number: 3235-0145
Expires: February 28, 2009
   Estimated average burden
hours per response       10.4

  
       

 

AMAG Pharmaceuticals, Inc.
(Name of Issuer)
 
 
Common Stock
(Title of Class of Securities)
 
 
 
00163U106
(CUSIP Number)
 
 
April 28, 2008
(Date of Event which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

o      Rule 13d-1(b)

x      Rule 13d-1(c)

o      Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).


Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.



CUSIP No. 00163U106 13G Page 2 of 10 Pages

1.           NAMES OF REPORTING PERSONS
  Great Point Partners, LLC
  I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY):
  37-1475292
   
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
  (a)            o    
 
  (b)            o    
 
3. SEC USE ONLY
 
 
4. CITIZENSHIP OR PLACE OF ORGANIZATION
  USA    
     
  5.           SOLE VOTING POWER
NUMBER OF SHARES    
BENEFICIALLY 6. SHARED VOTING POWER
OWNED BY EACH                                                                                    875,000
REPORTING PERSON    
WITH 7. SOLE DISPOSITIVE POWER
     
    8. SHARED DISPOSITIVE POWER
                                                                                       875,000
   
9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
             875,000    
   
10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN
  SHARES (See Instructions)
            o
   
11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
             5.14%    
   
12. TYPE OF REPORTING PERSON (See Instructions)
             OO    



CUSIP No. 00163U106 13G Page 3 of 10 Pages

1.           NAMES OF REPORTING PERSONS
  Dr. Jeffrey R. Jay, M.D.
  I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY):
 
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
  (a)            o
 
  (b)            o
 
3. SEC USE ONLY
 
 
4. CITIZENSHIP OR PLACE OF ORGANIZATION
  USA    
     
  5.           SOLE VOTING POWER
NUMBER OF SHARES                                                                                  0
BENEFICIALLY 6. SHARED VOTING POWER
OWNED BY EACH                                                                                  875,000
REPORTING PERSON    
WITH 7. SOLE DISPOSITIVE POWER
                                                                                     0
    8. SHARED DISPOSITIVE POWER
                                                                                      875,000
   
9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
             875,000    
   
10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN
  SHARES (See Instructions)
            o
   
11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
             5.14%    
   
12. TYPE OF REPORTING PERSON (See Instructions)
             IN    


CUSIP No. 00163U106 13G Page 4 of 10 Pages

1.           NAMES OF REPORTING PERSONS
  Mr. David Kroin
  I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY):
 
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
  (a)            o    
 
  (b)            o    
 
3. SEC USE ONLY    
 
 
4. CITIZENSHIP OR PLACE OF ORGANIZATION
  USA    
     
  5.           SOLE VOTING POWER
NUMBER OF SHARES                                                                                  0
BENEFICIALLY 6. SHARED VOTING POWER
OWNED BY EACH                                                                                   875,000
REPORTING PERSON    
WITH 7. SOLE DISPOSITIVE POWER
                                                                                     0
    8. SHARED DISPOSITIVE POWER
                                                                                     875,000
   
9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
  875,000    
   
10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN
  SHARES (See Instructions)
o
   
11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
  5.14%    
   
12. TYPE OF REPORTING PERSON (See Instructions)
  IN    


CUSIP No. 00163U106 13G Page 5 of 10 Pages

 

Item 1.              
     
  (a)          

Name of Issuer
 
   

AMAG Pharmaceuticals, Inc.
 
  (b)

Address of Issuer’s Principal Executive Offices
 
   

125 CambridgePark Drive, 6th Floor
Cambridge, MA 02140
 
Item 2.    
     
  (a)

Name of Person Filing
 
   

      Great Point Partners, LLC
      Dr. Jeffrey R. Jay, M.D.
      Mr. David Kroin
     
  The Reporting Persons have entered into a Joint Filing Agreement, dated May 8, 2008, a copy of which is filed with this Schedule 13G as Exhibit A, pursuant to which the Reporting Persons have agreed to file this statement jointly in accordance with the provisions of Rule 13d-1(k)(1) under the Act.
     
  (b)

Address of Principal Business Office, or if none, Residence

The address of the principal business office of each of the Reporting Persons is

      165 Mason Street, 3rd Floor
      Greenwich, CT 06830
     
  (c) Citizenship
     
  Great Point Partners, LLC is a limited liability company organized under the laws of the State of Delaware. Dr. Jeffrey R. Jay, M.D. is a citizen of the United States. Mr. David Kroin is a citizen of the United States.
     
  (d)

Title of Class of Securities

Common Stock
 
  (e)

CUSIP Number

00163U106
     
Item 3. If this statement is filed pursuant to §240.13d -1(b) or 240.13d. 2(b) or (c), check whether the person filing is a:
     
    Not Applicable.
     
  (a)      o

      Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o)
 
  (b)      o

      Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).
 
  (c)      o

      Insurance company as defined in Section 3(a)(19) of the Act (15. U.S.C. 78c).
 
  (d)      o

      Investment Company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
 


CUSIP No. 00163U106 13G Page 6 of 10 Pages

            (e)       o

      An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).
 
  (f)      o

      An employee benefit plan or endowment fund in accordance with §240.13d- 1(b)(1)(ii)(F).
 
  (g)      o

      A parent holding company or control person in accordance with §240.13d- 1(b)(1)(ii)(G).
 
  (h)      o

      A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).
 
  (i)      o

      A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment
      Company Act of 1940 (15 U.S.C. 80a-3).
 
  (j)      o

      Group, in accordance with §240.13d-1(b)(1)(ii)(J).
       
Item 4.           Ownership
       
 

Great Point Partners, LLC (“Great Point”) is the investment manager of Biomedical Value Fund, L.P. (“BVF”), and by virtue of such status may be deemed to be the beneficial owner of the 445,501 shares of Common Stock of the Issuer owned by BVF (the “BVF Shares”). Each of Dr. Jeffrey R. Jay, M.D. (“Dr. Jay”), as senior managing member of Great Point, and Mr. David Kroin (“Mr. Kroin”), as special managing member of Great Point, has voting and investment power with respect to the BVF Shares, and therefore may be deemed to be the beneficial owner of the BVF Shares.

Great Point is the investment manager of Biomedical Offshore Value Fund, Ltd. (“BOVF”), and by virtue of such status may be deemed to be the beneficial owner of the 429,499 shares of Common Stock (including 50,000 shares which BOVF has the right to acquire pursuant to the exercise of options held by BOVF) of the Issuer owned by BOVF (the “BOVF Shares”). Each of Dr. Jay, as senior managing member of Great Point, and Mr. Kroin, as special managing member of Great Point, has voting and investment power with respect to the BOVF Shares, and therefore may be deemed to be the beneficial owner of the BOVF Shares.

Each of Great Point, Dr. Jay and Mr. Kroin disclaim beneficial ownership of the BVF Shares and the BOVF Shares, except to the extent of their respective pecuniary interest.

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
       
  1. Great Point Partners, LLC
       
         
  (a)

Amount beneficially owned: 875,000
 
  (b)

Percent of class: 5.14%
 
  (c)

Number of shares as to which the person has:
 
    (i)

Sole power to vote or to direct the vote: - 0 -
 
    (ii)

Shared power to vote or to direct the vote: 875,000
 
    (iii)  

Sole power to dispose or to direct the disposition of: - 0 -
 
    (iv)

Shared power to dispose or to direct the disposition of: 875,000
         
  2.   Dr. Jeffrey R. Jay, M.D.

 


CUSIP No. 00163U106 13G Page 7 of 10 Pages

 

  (a)          

Amount beneficially owned: 875,000
 
  (b)

Percent of class: 5.14%
 
  (c)

Number of shares as to which the person has:
 
    (i)

Sole power to vote or to direct the vote:  -0-
 
    (ii)

Shared power to vote or to direct the vote: 875,000
 
    (iii)     

Sole power to dispose or to direct the disposition of:  -0-
 
    (iv)

Shared power to dispose or to direct the disposition of: 875,000
       
  3. Mr. David Kroin
       
  (a)

Amount beneficially owned: 875,000
 
  (b)

Percent of class: 5.14%
 
  (c)

Number of shares as to which the person has:
 
   (i)

Sole power to vote or to direct the vote:  -0-
 
   (ii)

Shared power to vote or to direct the vote: 875,000
 
   (iii)

Sole power to dispose or to direct the disposition of:  -0-
 
   (iv)

Shared power to dispose or to direct the disposition of: 875,000
       
Item 5.           Ownership of Five Percent or Less of a Class
       
                If this statement is being filed to report the fact that as of the date hereof each of the Reporting Persons has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].
       
       
Item 6. Ownership of More than Five Percent on Behalf of Another Person:
   
  See item 4.
       
Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being
  Reported on by the Parent Holding Company
       
  Not Applicable.
   
Item 8. Identification and Classification of Members of the Group
       
  Not Applicable.
       
Item 9. Notice of Dissolution of Group
   
  Not Applicable.
   
Item 10. Certification

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of


CUSIP No. 00163U106 13G Page 8 of 10 Pages


the securities and were not acquired and are not held in connection with or as participant in any transaction having that purpose or effect.

 

 

 


CUSIP No. 00163U106 13G Page 9 of 10 Pages


SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: May 8, 2008

  GREAT POINT PARTNERS, LLC  
       
  By:    /s/ Dr. Jeffrey R. Jay, M.D.  
    Dr. Jeffrey R. Jay, M.D.,  
    as senior managing member  
       
  /s/ Dr. Jeffrey R. Jay, M.D.  
  DR. JEFFREY R. JAY, M.D.  
       
  /s/ Mr. David Kroin  
  MR. DAVID KROIN  


Exhibit A

AGREEMENT REGARDING THE JOINT FILING OF SCHEDULE 13G

The undersigned hereby agree as follows:

          (i)           Each of them is individually eligible to use the Schedule 13G to which this Exhibit is attached, and such Schedule 13G is filed on behalf of each of them; and

          (ii)           Each of them is responsible for the timely filing of such Schedule 13G and any amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein; but none of them is responsible for the completeness or accuracy of the information concerning the other persons making the filing, unless such person knows or has reason to believe that such information is inaccurate.

Date: May 8, 2008


  GREAT POINT PARTNERS, LLC  
       
  By:    /s/ Dr. Jeffrey R. Jay, M.D.  
    Dr. Jeffrey R. Jay, M.D.,  
    as senior managing member  
       
  /s/ Dr. Jeffrey R. Jay, M.D.  
  DR. JEFFREY R. JAY, M.D.  
       
  /s/ Mr. David Kroin  
  MR. DAVID KROIN